REFERENCES
- Nick H, Acklin P, Lattmann R, et al. Development of tridentate iron chelators: from desferrithiocin to ICL670. Curr Med Chem. 2003;10:1065–1076.
- Hershko C, Konijn AM, Nick HP, Breuer W, Cabantchik ZI, Link G. ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture. Blood. 2001;97:1115–1122.
- Glickstein H, El RB, Link G, et al. Action of chelators in iron-loaded cardiac cells: accessibility to intracellular labile iron and functional consequences. Blood. 2006;108:3195–3203.
- Wood JC, Otto-Duessel M, Aguilar M, et al. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation. 2005;112:535–543.
- Galanello R, Piga A, Alberti D, Rouan MC, Bigler H, Sechaud R. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol. 2003;43:565–572.
- Nisbet-Brown E, Olivieri NF, Giardina PJ, et al. Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trial. Lancet. 2003;361:1597–1602.
- Piga A, Galanello R, Forni GL, et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica. 2006;91:873–80.
- Cappellini MD, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood. 2006;107:3455–3462.
- Vichinsky E, Onyekwere O, Porter J, et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol. 2007;136:501–508.
- Cohen AR, Glimm E, Porter JB. Effect of transfusional iron intake on response to chelation therapy in thalassemia major. Blood. 2008;111:583–587.
- Porter J, Galanello R, Saglio G, et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur J Haematol. 2008;80:168–176.
- Cappellini M, Elalfy MS, Kattamis A, et al. Efficacy and safety of once-daily, oral iron chelator deferasirox (Exjade®) in a large group of regularly transfused patients with β-thalassemia major. Blood. 2008;112: Abstract 3878.
- Porter JB, Piga A, Cohen A, et al. Safety of deferasirox (Exjade(R)) in patients with transfusion-dependent anemias and iron overload who achieve serum ferritin levels <1000 Ng/Ml during long-term treatment. Blood. 2008;112: Abstract 5423.
- Piga A, Kebaili K, Galanello R, et al. Cumulative efficacy and safety of 5-year deferasirox (Exjade®) treatment in pediatric patients with thalassemia major: a phase II multicenter prospective trial 2008. Blood 2008;112 Abstract 5413.
- Garbowski M, Eleftheriou P, Pennell D, Tanner M, Porter JB. Impact of compliance, ferritin and LIC on long-term trends in myocardial T2* with deferasirox. Blood. 2008;112: Abstract 116.
- Taher A, El-Beshlawy A, Elalfy MS, et al. Efficacy and safety of deferasirox, an oral iron chelation, in heavily iron-overloaded patients with β-thalassemia: the ESCALATOR study. Eur J Haematol. 2009;82:458–465.
- Taher A, Cappellini D, Vichinsky E, et al. Efficacy and safety of deferasirox doses of >30 mg/d per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol. [Epub ahead of print].
- Pennell D, Sutcharitchan P, El-Beshlawy A, et al. Efficacy and safety of deferasirox (Exjade®) in preventing cardiac iron overload in β-thalassemia patients with normal baseline cardiac iron: results from the cardiac substudy of the EPIC trial. Blood. 2008;112: Abstract 3874.
- Pennell DJ, Porter JB, Cappellini MD, et al. Efficacy and safety of deferasirox (Exjade®) in reducing cardiac iron in patients with β-thalassemia major: results from the cardiac substudy of the EPIC trial. Blood. 2008;112: Abstract 3873.